EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 337 filers reported holding EXELIXIS INC in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $400 | -12.1% | 18,290 | -23.1% | 0.01% | 0.0% |
| Q2 2023 | $455 | -1.5% | 23,790 | 0.0% | 0.01% | -14.3% |
| Q1 2023 | $462 | +57.7% | 23,790 | +30.1% | 0.01% | +75.0% |
| Q4 2022 | $293 | -99.9% | 18,290 | 0.0% | 0.00% | -20.0% |
| Q3 2022 | $287,000 | -88.6% | 18,290 | -86.8% | 0.01% | -90.0% |
| Q2 2021 | $2,524,000 | -19.9% | 138,538 | -0.7% | 0.05% | -24.2% |
| Q1 2021 | $3,153,000 | +10.9% | 139,568 | -1.5% | 0.07% | 0.0% |
| Q4 2020 | $2,843,000 | -15.5% | 141,662 | +2.9% | 0.07% | -25.0% |
| Q3 2020 | $3,366,000 | +2.3% | 137,681 | -0.6% | 0.09% | -7.4% |
| Q2 2020 | $3,290,000 | +39.9% | 138,568 | +1.5% | 0.10% | +25.0% |
| Q1 2020 | $2,352,000 | +92.8% | 136,581 | +97.3% | 0.08% | +145.2% |
| Q4 2019 | $1,220,000 | -47.0% | 69,220 | -46.8% | 0.03% | -57.5% |
| Q3 2019 | $2,303,000 | -13.8% | 130,200 | +4.1% | 0.07% | -14.1% |
| Q2 2019 | $2,673,000 | – | 125,060 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 17,416,738 | $422,007,000 | 64.06% |
| Matrix Capital Management Company, LP | 15,117,460 | $366,296,000 | 11.71% |
| Rhenman & Partners Asset Management AB | 1,050,000 | $25,442,000 | 3.25% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 254,334 | $6,163,000 | 2.40% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 790,148 | $19,145,000 | 1.30% |
| Jupiter Investment Management Ltd | 4,182,760 | $101,348,000 | 1.06% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 50,818 | $1,231,000 | 0.70% |
| C M BIDWELL & ASSOCIATES LTD | 17,475 | $423,000 | 0.65% |
| QCM Cayman, Ltd. | 9,562 | $232,000 | 0.60% |
| Handelsinvest Investeringsforvaltning | 98,500 | $2,387,000 | 0.56% |